Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters\u2014albeit on an even grander scale than 2025\u2019s plenty-respectable slate of major rollouts.
\nAccording to Evaluate\u2019s annual analysis of the biggest potential drug launches of the coming year, the top 10 most anticipated meds could generate a combined $45.9 billion in annual sales by 2032.
\nThat\u2019s a massive jump from the $29 billion figure that Evaluate calculated for last year\u2019s top 10, which itself was the highest total in years.<\/p>\n
In fact, combined sales from the top two drugs on the 2026 list alone are predicted to equal the 2025 total: Novo Nordisk\u2019s CagriSema and Eli Lilly\u2019s orforglipron\u2014both candidates in the perennially hot area of obesity and Type 2 diabetes\u2014are on track to rake in a respective $17.2 billion and $11.8 billion within just a few years, per the analysis.<\/p>\n
There\u2019s a steep dropoff from that duo to the remaining eight entries on the 2026 docket, which include meds from the likes of Gilead Sciences, Johnson & Johnson, AstraZeneca and other biopharmas big and small, spanning a range of indications from breast cancer to essential tremor. Predicted 2032 sales for the octet weigh in at a more modest\u2014though still blockbuster-worthy\u2014range of $1.7 billion to $2.5 billion each.<\/p>\n
Of course, it remains to be seen not only whether the anointed drugs will reach those lofty sales goals by 2032, but also, more pressingly, whether they\u2019ll secure the anticipated approvals this year so they can begin racking up any sales at all.
\nOn the second point, at least, Evaluate\u2019s crystal ball has recently been particularly clear: An impressive nine of 2025\u2019s top 10 earned their predicted approvals before the end of last year, with the only holdout Sanofi\u2019s multiple sclerosis candidate tolebrutinib, which was rejected by the FDA in the final days of December.<\/p>\n
If that accuracy streak stretches to this year\u2019s slate, the industry is in for quite the downpour of high-profile approvals and skyrocketing sales.<\/p>\n
Read on for the full list of the top 10 most anticipated drug launches of 2026, and revisit last year\u2019s roundup here.<\/p>\n
\u2022 CagriSema
\nManufacturer: Novo Nordisk
\nIndications: Obesity and Type 2 Diabetes
\nSales Forecast by 2032: $17.2 billion<\/p>\n
\u2022Orforglipron
\nManufacturer: Eli Lilly
\nIndications: Obesity and Type 2 Diabetes
\nSales Forecast by 2032: $11.8 billion<\/p>\n
\u2022Anito-cel
\nManufacturer: Gilead Sciences \/ Arcellx
\nIndications: Multiple Myeloma
\nSales Forecast by 2032: $2.5 billion<\/p>\n
\u2022Brepocitinib
\nManufacturer: Roivant Sciences
\nIndications: Dermatomyositis
\nSales Forecast by 2032: $2.3 billion<\/p>\n
\u2022Icotrokinra
\nManufacturer: Johnson & Johnson \/ Protagonist
\nIndications: Autoimmune Diseases
\nSales Forecast by 2032: $2.2 billion<\/p>\n
\u2022Gedatolisib
\nManufacturer: Celcuity
\nIndications: Breast Cancer
\nSales Forecast by 2032: $2.1 billion<\/p>\n
\u2022Ulixacaltamide
\nManufacturer: Praxis Precision Medicines
\nIndications: Essential Tremor
\nSales Forecast by 2032: $2.1 billion<\/p>\n
\u2022Baxdrostat
\nManufacturer: AstraZeneca
\nIndications: High Blood Pressure
\nSales Forecast by 2032: $2 billion<\/p>\n
\u2022Camizestrant
\nManufacturer: AstraZeneca
\nIndications: Hormone Receptor-Positive Breast Cancer
\nSales Forecast by 2032: $2 billion<\/p>\n
\u2022 Atacicept
\nManufacturer: Vera Therapeutics
\nIndications: IgA Nephropathy
\nSales Forecast by 2032: $1.7 billion<\/p>\n","protected":false},"excerpt":{"rendered":"
Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters\u2014albeit on an even grander scale than 2025\u2019s plenty-respectable slate of major rollouts. According to Evaluate\u2019s annual analysis of the biggest potential drug launches of the coming year, the top 10 most anticipated meds could generate a combined $45.9 billion in annual sales […]<\/p>\n","protected":false},"author":2,"featured_media":2520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[791],"class_list":{"0":"post-2519","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sitefansalaran-editors-choice","8":"tag-top-10-most-anticipated-drug-launches-of-2026"},"yoast_head":"\n